Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Gaede, P. Vedel, N. Larsen, G. Jensen, H. Parving, O. Pedersen (2003)
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.The New England journal of medicine, 348 5
F. Galletti, P. Strazzullo, B. Capaldo, R. Carretta, F. Fabris, L. Ferrara, N. Glorioso, A. Semplicini, M. Mancini (1999)
Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS).Journal of hypertension, 17 3
D. Giugliano, D. Giugliano, A. Ceriello, A. Ceriello, G. Paolisso, G. Paolisso (1995)
Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress?Metabolism: clinical and experimental, 44 3
T. Gundersen, J. Kjekshus (1983)
Timolol Treatment After Myocardial Infarction in Diabetic PatientsDiabetes Care, 6
Å. Hjalmarson, J. Herlitz, I. Málek, L. Rydén, A. Vedin, A. Waldenström, H. Wedel, D. Elmfeldt, S. Holmberg, G. Nyberg, K. Swedberg, F. Waagstein, J. Waldenström, L. Wilhelmsen, C. Wilhelmsson (1981)
EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised TrialThe Lancet, 318
(1986)
Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1Lancet, II
P. Verdecchia, G. Reboldi, F. Angeli, C. Borgioni, R. Gattobigio, L. Filippucci, Silvia Norgiolini, C. Bracco, C. Porcellati (2004)
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive SubjectsHypertension: Journal of the American Heart Association, 43
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension, 42 6
H. Lowel, W. Koenig, S. Engel (2000)
The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up studyDiabetologia, 43
L. Lind, C. Berne, T. Pollare, H. Lithell (1994)
Metabolic effects of isradipine as monotherapy or in combination with pindolol during long‐term antihypertensive treatmentJournal of Internal Medicine, 236
P. Poole‐Wilson, K. Swedberg, J. Cleland, A. Lenarda, P. Hanrath, M. Komajda, J. Lubsen, B. Lutiger, M. Metra, W. Remme, C. Torp-Pedersen, A. Scherhag, A. Skene (2003)
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialThe Lancet, 362
(1985)
A randomised placebo-controlled international trial. The MIAMI Trial Research GroupEur Heart J, 6
B. Karlson, J. Herlitz, O. Wiklund, P. Pettersson, P. Hallgren, Å. Hjalmarson (1992)
Characteristics and prognosis of patients with acute myocardial infarction in relation to whether they were treated in the coronary care unit or in another ward.Cardiology, 81 2-3
T. Celik, A. Iyisoy, H. Kurşaklioğlu, E. Kardeşoğlu, S. Kılıç, H. Turhan, Mahmut Yilmaz, O. Ozcan, H. Yaman, E. Işik, F. Fıcı (2006)
Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patientsJournal of Hypertension, 24
H. Holzgreve, R. Nakov, K. Beck, H. Janka (2003)
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.American journal of hypertension, 16 5 Pt 1
J. Herlitz, Å. Hjalmarson (1985)
Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.European heart journal, 6 3
B. Biondi, E. Palmieri, M. Klain, M. Schlumberger, S. Filetti, G. Lombardi (2005)
Subclinical hyperthyroidism: clinical features and treatment options.European journal of endocrinology, 152 1
(1998)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet, 352
S. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, M. Laakso (1998)
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.The New England journal of medicine, 339 4
G. Grassi, B. Cattaneo, G. Seravalle, M. Colombo, F. Cavagnini, G. Mancia (1996)
Obesity and the sympathetic nervous system.Blood pressure. Supplement, 1
K. Malmberg, A. Norhammar, H. Wedel, L. Rydén (1999)
Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Glycometabolic State at Admission : Important Risk Marker of Mortality in
L. Poirier, J. Cléroux, A. Nadeau, Y. Lacourciére (2001)
Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patientsJournal of Hypertension, 19
I. Lager, G. Blohmé, Ulf Smith (1979)
EFFECT OF CARDIOSELECTIVE AND NON-SELECTIVE β-BLOCKADE ON THE HYPOGLYCÆMIC RESPONSE IN INSULIN-DEPENDENT DIABETICSThe Lancet, 313
K. Khaw, N. Wareham, R. Luben, S. Bingham, S. Oakes, A. Welch, N. Day (2001)
Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)BMJ : British Medical Journal, 322
T. Yue, Hung‐Yuan Cheng, P. Lysko, P. McKenna, R. Feuerstein, J. Gu, K. Lysko, L. Davis, G. Feuerstein (1992)
Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.The Journal of pharmacology and experimental therapeutics, 263 1
K. Malmberg, A. Norhammar, H. Wedel (1999)
Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) studyCirculation, 99
S. Colagiuri, C. Cull, R. Holman (2002)
Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.Diabetes care, 25 8
Michael Jonas, H. Reicher-Reiss, V. Boyko, A. Shotan, L. Mandelzweig, U. Goldbourt, S. Behar (1996)
Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group.The American journal of cardiology, 77 15
T. Pollare, H. Lithell, C. Morlin, Hans Prantare, A. Hvarfner, S. Ljunghall (1989)
Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups.Journal of hypertension, 7 7
E. Ohlstein, A. Arleth, B. Storer, A. Romanic (1998)
CARVEDILOL INHIBITS ENDOTHELIN-1 BIOSYNTHESIS IN CULTURED HUMAN CORONARY ARTERY ENDOTHELIAL CELLSJournal of Molecular and Cellular Cardiology, 30
A. Dornhorst, S. Powell, J. Pensky (1985)
AGGRAVATION BY PROPRANOLOL OF HYPERGLYCAEMIC EFFECT OF HYDROCHLOROTHIAZIDE IN TYPE II DIABETICS WITHOUT ALTERATION OF INSULIN SECRETIONThe Lancet, 325
E.J. Feskens, J. Tuomilehto, J.H. Stengard (1995)
Hypertension and overweight associated with hyperinsulinaemia and glucose tolerance: a longitudinal study of the Finnish and Dutch cohorts of the Seven Countries StudyDiabetologia, 38
A. Al-hesayen, E. Azevedo, J. Floras, Shauna Hollingshead, G. Lopaschuk, J. Parker (2005)
Selective versus nonselective β‐adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilizationEuropean Journal of Heart Failure, 7
D. Giugliano, R. Acampora, R. Marfella, N. Rosa, P. Ziccardi, R. Ragone, L. Angelis, F. D'onofrio (1997)
Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and HypertensionAnnals of Internal Medicine, 126
P. Deedwania, T. Giles, M. Klibaner, J. Ghali, J. Herlitz, P. Hildebrandt, J. Kjekshus, J. Špinar, J. Vítovec, H. Stanbrook, J. Wikstrand (2005)
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.American heart journal, 149 1
T. Pollare, H. Lithell, I. Selinus, C. Berne (1988)
Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertensionDiabetologia, 31
Jawahar Mehta, Larry Lopez, Liying Chen, Ode Cox (1994)
Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol.The American journal of cardiology, 74 9
S. Haas, T. Vos, R. Gilbert, H. Krum (2003)
Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.American heart journal, 146 5
K. Dunder, L. Lind, B. Zethelius, L. Berglund, H. Lithell (2003)
Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort studyBMJ : British Medical Journal, 326
G. Bakris, V. Fonseca, R. Katholi, J. McGill, F. Messerli, R. Phillips, P. Raskin, R. Oakes, K. Anderson, D. Bell (2005)
Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trialAcc Current Journal Review, 14
C. Furberg, J. Wright, B. Davis, J. Cutler, M. Alderman, H. Black, W. Cushman, R. Grimm, L. Haywood, F. Leenen, S. Oparil, J. Probstfield, P. Whelton, C. Nwachuku, D. Gordon, M. Proschan, Paula Einhom, C. Ford, L. Piller, I. Dunn, D. Goff, S. Pressel, Judy Bettencourt, Barbara DeLeon, Lara Simpson, J. Blanton, T. Geraci, Sandra Walsh, C. Nelson, Mahboob Rahman, Anne Juratovac, R. Pospíšil, L. Carroll, Sheila Sullivan, J. Russo, G. Barone, Rudy Christian, S. Feldman, T. Lucente, D. Calhoun, Kimo Jenkins, Peggy McDowell, Janice Johnson, C. Kingry, J. Alzate, K. Margolis, Leslie Holland-Klemme, B. Jaeger, J. Williamson, G. Louis, Pamela Ragusa, A. Williard, R. Ferguson, J. Tanner, J. Eckfeldt, R. Crow, J. Pelosi (2002)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA, 288 23
O. Samuelsson, K. Pennert, O. Andersson, G. Berglund, T. Hedner, B. Persson, H. Wedel, L. Wilhelmsen (1996)
Diabetes mellitus and raised serum triglyceride concentration in treated hypertension—are they of prognostic importance? Observational studyBMJ, 313
H. Lithell, T. Pollare, B. Vessby (1992)
Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients.Blood pressure, 1 2
M. Stearne, S. Palmer, M. Hammersley, S. Franklin, R. Spivey, J. Levy, C. Tidy, N. Bell, J. Steemson, B. Barrow, R. Coster, K. Waring, L. Nolan, E. Truscott, N. Walravens, B. Cook, H. Lampard, C. Merle, P. Parker, J. Mcvittie, I. Draisey, L. Murchison, A. Brunt, M. Williams, D. Pearson, X. Petrie, M. Lean, D. Walmsley, F. Lyall, E. Christie, J. Church, E. Thomson, A. Farrow, J. Stowers, M. Stowers, K. McHardy, N. Patterson, A. Wright, N. Levi, A. Shearer, R. Thompson, G. Taylor, S. Rayton, M. Bradbury, A. Glover, A. Smyth-Osbourne, C. Parkes, J. Graham, P. England, S. Gyde, C. Eagle, B. Chakrabarti, J. Smith, J. Sherwell, E. Kohner, A. Dornhorst, M. Doddridge, M. Dumskyj, S. Walji, P. Sharp, M. Sleightholm, G. Vanterpool, C. Rose, G. Frost, M. Roseblade, S. Elliott, S. Forrester, M. Foster, K. Myers, R. Chapman, J. Hayes, T. Henry, M. Featherston, G. Archbold, M. Copeland, R. Harper, I. Richardson, S. Martín, H. Davison, D. Hadden, L. Kennedy, A. Atkinson, A. Culbert, C. Hegan, H. Tennet, N. Webb, I. Robinson, J. Holmes, P. Bell, D. McCance, J. Rutherford, S. Nesbitt, A. Spathis, S. Hyer, M. Nanson, J. James, J. Tyrell, C. Davis, P. Strugnell, M. Booth, H. Petrie, D. Clark, B. Rice, S. Hulland, J. Barron, J. Yudkin, B. Gould, J. Singer, A. Badenock, M. Eckert, K. Alibhai, E. Marriot, C. Cox, R. Price, M. Fernandez, A. Ryle, S. Clarke, G. Wallace, E. Mehmed, S. Macfarlane, R. Greenwood, J. Wilson, M. Denholm, R. Temple, K. Whitfield, F. Johnson, C. Munroe, S. Gorick, E. Duckworth, M. Flatman, S. Rainbow, L. Borthwick, D. Wheatcroft, R. Seaman, R. Christie, W. Wheatcroft, P. Musk, J. White, S. McDougal, M. Bond, P. Raniga, R. Newton, R. Jung, C. Roxburgh, B. Kilgallon, L. Dick, N. Waugh, S. Kilby, A. Ellingford, J. Burns, C. Fox, M. Holloway, H. Coghill, N. Hein, A. Fox, W. Cowan, M. Richard, K. Quested, S. Evans, R. Paisey, N. Brown, A. Tucker, R. Paisey, F. Garrett, J. Hogg, P. Park, K. Williams, Philip Harvey, R. Wilcocks, S. Mason, J. Frost, C. Warren, P. Rocket, L. Bower, J. Roland, D. Brown, J. Youens, K. Stanton-King, H. Mungall, W. Maddison, D. Donnelly, S. King, P. Griffin, S. Smith, S. Church, G. Dunn, Andrew Wilson, K. Palmer, P. Brown, D. Humphriss, A. Davidson, R. Rose, L. Armistead, S. Townsend, P. Poon, I. Peacock, N. Culverwell, M. Charlton, B. Connolly, J. Peacock, J. Barrett, J. Wain, W. Beeston, G. King, P. Hill, A. Boulton, A. Robertson, Katoulis, A. Olukoga, H. McDonald, S. Kumar, F. Abouaesha, B. Abuaisha, E. Knowles, S. Higgins, J. Booker, J. Sunter, K. Breislin, R. Parker, P. Raval, J. Curwell, H. Davenport, G. Shawcross, A. Prest, J. Grey, H. Cole, C. Sereviratne, R. Young, T. Dornan, J. Clyne, M. Gibson, I. O'Connell, L. Wong, S. Wilson, K. Wright, C. Wallace, D. McDowell, A. Burden, E. Sellén, R. Gregory, M. Roshan, N. Vaghela, M. Burden, C. Sherriff, J. Clarke, J. Grenfell, J. Tooke, K. Macleod, C. Searnark, M. Rammell, C. Pym, J. Stockman, C. Yeo, J. Piper, L. Leighton, E. Green, M. Hoyle, K. Jones, A. Hudson, A. James, A. Shore, A. Higham, B. Martin (1998)
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39BMJ, 317
K. Malminiemi, J. Lahtela, O. Malminiemi, K. Ala-Kaila, R. Huupponen (1998)
Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents.Journal of cardiovascular pharmacology, 31 1
L. Lind, H. Lithell (1993)
Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia.American heart journal, 125 5 Pt 2
S. Deacon, A. Karunanayake, D. Barnett (1977)
Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics.British Medical Journal, 2
M. Reiter (2004)
Cardiovascular drug class specificity: β-blockersProgress in Cardiovascular Diseases, 47
W. Kannel, D. McGee (1979)
Diabetes and Cardiovascular Risk Factors: The Framingham StudyCirculation, 59
R. Smith, D. Warren (1982)
Effect of acute oral beta adrenergic blockade on muscle blood flow in man.Cardiovascular research, 16 4
S. Jacob, B. Balletshofer, E. Henriksen, A. Volk, Birgit Mehnert, K. Löblein, Hans Häring, K. Rett (1999)
Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers.Blood pressure, 8 5-6
M. Weinberger (1985)
Antihypertensive therapy and lipids. Evidence, mechanisms, and implications.Archives of internal medicine, 145 6
(1992)
MRC Working PartyBMJ, 304
O. Hansen, B. Johansson, P. Nilsson‐Ehle, B. Eklund, I. Ohlsson, E. Palenmark, A. Pauler, K. Svensson (1994)
Effects of carvedilol on the metabolic, hemodynamic, and electrocardiographic responses to increased plasma epinephrine in normal subjects.Journal of cardiovascular pharmacology, 24 6
(2003)
HLA-MATCHING AND PRETRANSPLANT BLOOD TRANSFUSIONS IN CADAVERIC RENAL TRANSPLANTATION—A CHANGING PICTURE WITH CYCLOSPORIN
M. Arumanayagam, Skiva Chan, Shi-Ruo Tong, J. Sanderson (2001)
Antioxidant Properties of Carvedilol and Metoprolol in Heart Failure: A Double-Blind Randomized Controlled TrialJournal of Cardiovascular Pharmacology, 37
F. Gustafsson, C. Torp-Pedersen, M. Seibaek, H. Burchardt, L. Køber (2004)
Effect of age on short and long-term mortality in patients admitted to hospital with congestive heart failure.European heart journal, 25 19
G. Bakris, V. Fonseca, R. Katholi, J. McGill, F. Messerli, R. Phillips, P. Raskin, J. Wright, R. Oakes, M. Lukas, K. Anderson, D. Bell (2004)
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.JAMA, 292 18
P. Lysko, Christine Webb, J. Gu, E. Ohlstein, R. Ruffolo, Tian-Li Yue (2000)
A comparison of carvedilol and metoprolol antioxidant activities in vitro.Journal of cardiovascular pharmacology, 36 2
I. Reid, Jenny Lucas, D. Wattie, A. Horne, M. Bolland, G. Gamble, J. Davidson, A. Grey (2005)
Effects of a β-Blocker on Bone Turnover in Normal Postmenopausal Women: A Randomized Controlled TrialThe Journal of Clinical Endocrinology and Metabolism, 90
H. Löwel, W. Koenig, S. Engel, A. Hörmann, U. Keil (2000)
The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment?Diabetologia, 43
I. Gustafsson, P. Hildebrandt, M. Seibaek (2000)
Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study GroupEur Heart J, 21
L. Lind, C. Berne, T. Pollare, H. Lithell (1995)
Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study.Journal of human hypertension, 9 2
S. Jacob, K. Rett, M. Wicklmayr, B. Agrawal, H. Augustin, G. Dietze (1996)
Differential effect of chronic treatment with two beta‐blocking agents on insulin sensitivity: the carvedilol‐metoprolol studyJournal of Hypertension, 14
J. Kjekshus, E. Gilpin, Geraldine Cali, A. Blackey, H. Henningj, J. Ross (1990)
Diabetic patients and beta-blockers after acute myocardial infarction.European heart journal, 11 1
F. Turnbull (2003)
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsThe Lancet, 362
B. Dahlöf, R. Devereux, S. Kjeldsen, S. Julius, G. Beevers, U. Faire, F. Fyhrquist, H. Ibsen, Krister Kristiansson, O. Lederballe‐Pedersen, L. Lindholm, M. Nieminen, P. Omvik, S. Oparil, H. Wedel (2002)
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 359
C. Torp-Pedersen, J.G. Cleland, A. Lenarda (2005)
Carvedilol reduces the risk for new onset of diabetes related adverse events in heart failure compared to metoprolol: results of the COMET study [abstract]J Am Coll Cardiol, 45
A. Haenni, H. Lithell (1994)
Treatment with a β-blocker with β2-agonism improves glucose and lipid metabolism in essential hypertensionMetabolism-clinical and Experimental, 43
K. Yasunari, K. Maeda, Munehiro Nakamura, Takanori Watanabe, J. Yoshikawa, A. Asada (2004)
Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension.The American journal of medicine, 116 7
Stephan Jacob, K. Rett, E. Henriksen (1998)
Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?American journal of hypertension, 11 10
B. Dahlöf, L. Hansson, L. Lindholm, B. Scherstén, T. Ekbom, P. Wester (1991)
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)The Lancet, 338
R. DeFronzo, E. Ferrannini (1991)
Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular DiseaseDiabetes Care, 14
R. Shorr, W. Ray, J. Daugherty, M. Griffin (1997)
Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas.JAMA, 278 1
K. Malmberg, J. Herlitz, Aå. Hjakmarson, L. Rydén (1989)
Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies.European heart journal, 10 5
T. Pollare, H. Lithell, I. Selinus, C. Berne (1989)
Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.British Medical Journal, 298
D. Bell (2004)
Advantages of a third-generation β-blocker in patients with diabetes mellitusAmerican Journal of Cardiology, 93
J. Gurwitz, R. Goldberg, Z. Chen, J. Gore, J. Alpert (1992)
Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly.The American journal of medicine, 93 6
M. Olsen, E. Fossum, A. Høieggen, K. Wachtell, E. Hjerkinn, S. Nesbitt, U. Andersen, R. Phillips, C. Gaboury, H. Ibsen, S. Kjeldsen, S. Julius (2005)
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudyJournal of Hypertension, 23
I. Gustafsson, P. Hildebrandt, M. Seibæk, T. Melchior, C. Torp-Pedersen, L. Køber, P. Kaiser-Nielsen (2000)
Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimenEuropean Heart Journal, 21
R. Turner, C. Fox, Matthews, H. Mcelroy, C. Cull, R. Holman, P. Neil, D. Hadden, D. Wright, É. Manley, I. Stratton, Uk Diabetes, E. Kohner, Frighi, Michael Gnant (1998)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.The Lancet
Neese Jw, Duncan Bayse, Robinson M, Cooper T, Stewart C, J. Fuller, M. Shipley, G. Rose, J. Jarrett, H. Keen (1983)
Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study.British Medical Journal (Clinical research ed.), 287
J. Barzilay, S. Pressel, B. Davis, K. Margolis, J. Cutler, S. Ong, J. Basile, L. Sadler, J. Summerson, P. Whelton (2004)
OR-2: Risk and impact of incident glucose disorders in hypertensive older adults treated with an ace inhibitor, a diuretic, or a calcium channel blocker: a report from the allhat trialAmerican Journal of Hypertension, 17
A. Niklason, T. Hedner, L. Niskanen, J. Lanke (2004)
Development of diabetes is retarded by ACE inhibition in hypertensive patients – a subanalysis of the Captopril Prevention Project (CAPPP)Journal of Hypertension, 22
T. Pischon, Arya Sharma (2001)
Use of beta‐blockers in obesity hypertension: potential role of weight gainObesity Reviews, 2
A. Rocchini (1992)
Cardiovascular regulation in obesity-induced hypertension.Hypertension, 19 1 Suppl
D. Giugliano, R. Acampora, R. Marfella (1997)
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trialAnn Intern Med, 126
Although β-adrenoceptor antagonists (β-blockers) have effects on metabolism via their mechanism as blockers of adrenergic stimulation, most interest in the metabolic effects of β-blockers is caused by their effect on glucose metabolism. Strict metabolic control and management of cardiovascular risk factors in patients with diabetes mellitus has proven to be of great importance in the improvement of prognosis. β-Blockers are necessary tools for the treatment of heart failure and hypertension. The use of β-blockers in patients with diabetes mellitus has been controversial because of fear of deterioration of metabolic control of glucose and lipids and blunting of the symptoms of hypoglycemia. Currently, it appears that there is a beneficial metabolic effect with the third-generation β-blocker carvedilol. Comparisons have been made between the second-generation β-blocker metoprolol and carvedilol, with a clear advantage for carvedilol in terms of metabolic control. In the GEMINI (Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives) trial, a decrease of 9.1% (p = 0.004) in insulin resistance, compared with baseline values, was seen in patients treated with carvedilol, whereas no significant difference was seen in the group of patients treated with metoprolol. Additionally, an increase in glycosylated hemoglobin of 0.15% from baseline was seen in the metoprolol group (p < 0.001) compared with no significant change in the carvedilol group. These findings indicate that, as carvedilol exerts favorable effects on glucose metabolism compared with metoprolol, patients with diabetes mellitus could benefit from treatment with carvedilol rather than metoprolol. The mechanisms behind these findings are not yet fully understood. Several mechanisms have been suggested, and special interest has been paid to the investigation of the potential beneficial role of the β2- and α1-adrenoceptor-blocking effects of carvedilol, along with its known antioxidant properties.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.